Lé, Ana Maria http://orcid.org/0000-0002-3559-0413
Torres, Tiago http://orcid.org/0000-0003-0404-0870
Article History
Accepted: 10 October 2021
First Online: 27 October 2021
Change Date: 14 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40257-021-00657-w
Declarations
:
: No funding has been received for the preparation of this article.
: Ana Maria Lé has no conflicts of interest to declare. Tiago Torres declares the following conflicts of interest: AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: AL and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.